News | April 09, 2026
Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study
The results were consistent across both the 10 mg and 40 mg treatment arms
The results were consistent across both the 10 mg and 40 mg treatment arms
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Safety was equally impressive. ENV-294 was well tolerated
Subscribe To Our Newsletter & Stay Updated
